BioMAP® System ELECT provides the flexibility to create a customized BioMAP Panel by choosing from available individual or multiple BioMAP Systems. As for all BioMAP human phenotypic profiling, your test agent(s) will generate a BioMAP profile based on changes in protein biomarker readouts within each individual system environment.
With BioMAP System ELECT, your test agents are profiled at four or eight concentrations, in triplicate, for greater statistical power. All BioMAP Systems included in BioMAP Diversity PLUS®, BioMAP T Cell Autoimmune Panel, BioMAP Oncology Panels and the BioMAP Fibrosis Panel are appropriate for a System ELECT project. Non-stimulated control systems are available for select systems.
System ELECT Advantages
- Obtain rigorous statistical comparison of potencies on sentinel biomarker activities
- Gain insights for dosing guidance
- Guide structure-activity-relationship design based on activities correlated with chemical structures
The BioMAP System ELECT Service provides granular information on changes to translational biomarker levels following test agent treatment in one or more BioMAP system of choice. Shown here is the BioMAP HDFSAg System modeling chronic inflammation and T cell effector responses related to T cell activation, in the context of stromal tissue. Therapeutics targeted at specific inflammatory conditions where T cells play a key role are appropriate for modeling in BioMAP HDFSAg and include rheumatoid arthritis, psoriasis, Crohn’s disease, chronic inflammation, autoimmune disease, fibrosis, and wound healing biology.
Biomarker Responses to Infliximab Treatment of a BioMAP Model of Stromal Tissue Inflammation
Figure. Assessment of the biologic infliximab, an antibody directed against TNFα, in a model of chronic inflammation and T cell responses in the context of stromal tissue, identifies responses relevant for immunosuppressive and anti-inflammatory function. Infliximab was not cytotoxic at tested concentrations, close to clinical doses. Of the 17 translational readouts in the BioMAP HDFSAg system, infliximab decreased 14 and had no effect on three. Decreased inflammation-related activities include VCAM-1, MCP-1, sTNFα, MIG, IP-10 and IL-8. Decreased immunomodulatory activities include M-CSF, sIL-2, sIL-6, sIL-10, sIL-17A and sIL-17F. For the tissue remodeling activities assessed in BioMAP HDFSAg, sVEGF and MMP-1 were decreased while Collagen 1 changes did not meet the robust annotation criteria. The BioMAP HDFSAg System is comprised of human primary cell co-cultures of PBMCs together with dermal fibroblasts, stimulated with sub-mitogenic levels of T cell receptor ligands. Tested concentrations of infliximab, a mouse-human chimeric monoclonal anti-TNFα antibody, are indicated.
